3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
3
Phase 1
3
Phase 3
2
Phase EARLY_PHASE1
1
Phase 2
1
Status
Recruiting
3
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Tumor-Agnostic
1
Thoracic
1
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
118
pembrolizumab
104
Specimen Handling
104
Magnetic Resonance Spectroscopy
94
fludarabine
92
Biopsy
77
Injections
53
Nivolumab
43
Bevacizumab
41
Fluorouracil
38
venetoclax
37
Cisplatin
36
Paclitaxel
35
Carboplatin
35
Cetuximab
34
Radiotherapy
31
Oxaliplatin
30
fludarabine phosphate
29
Leucovorin
28
Gemcitabine
28
Drug Therapy
25
Ipilimumab
23
Immunotherapy, Adoptive
23
Azacitidine
23
Radiation
21
Irinotecan
21
Temozolomide
20
Doxorubicin
20
tislelizumab
19
atezolizumab
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 1
×
Recruiting
×
AZD5305
×
Clear all
NCT06713369
2026-03-04
AZD5305
AstraZeneca
Phase 1
Recruiting
8 enrolled
NCT05938270
2026-02-24
ASCERTAIN
AstraZeneca
Phase 1
Recruiting
120 enrolled
NCT04550104
2025-12-19
CONCORDE
University of Leeds
Phase 1
Recruiting
200 enrolled